ByteBrief
We're a portrait publication through and through. Turn your phone back and your briefing picks up right where you left it.
(We tried widescreen once. It wasn't us.)
Abcuro raised $66 million in Series D funding. The financing will support the company's clinical development programs. The round advances Abcuro's work in developing therapies for autoimmune diseases and cancer.
Tap to vote and see what everyone thinks.
Summary by ByteBrief